SFX by Ex Libris Inc.

Title:	Mass Spectrometric Characterization of Transglutaminase Based Site-Specific Antibody–Drug Conjugates
Source:	Bioconjugate Chemistry [1043-1802] Farias, Santiago yr:2014

Basic

Full text

Full text available via American Chemical Society Journals

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	"Recent progress in transglutaminase-mediated assembly of antibody-drug conjugates." Analytical biochemistry. 595: 113615-.
description	2.	Chen, T. "Antibody-drug conjugate characterization by chromatographic and electrophoretic techniques." Journal of chromatography. B 1032 (2016): 39-50.
description	3.	Strop, P. "Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates." Chemistry & biology 20.2 (2013): 161-167.
description	4.	Eichinger, S. "Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa." European journal of clinical investigation 39.8 (2009): 707-713.
description	5.	"Mutation detection of CYP21A2 gene in nonclassical congenital adrenal hyperplasia patients with premature pubarche." Advanced biomedical research. 5.1: 33-33.
description	6.	"to the Consolidating State of (Pseudo-)technocratic Governance." British journal of law and society. 44.1: 56-78.
description	7.	Janthur, W.-D. D. "Drug conjugates such as antibody drug conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice." International journal of molecular sciences 13.12 (2012): 16020-16795.
description	8.	Shani, J. "Preparation and control of radiopharmaceuticals in hospitals." Journal of radioanalytical chemistry 62.1 (1981): 291-.
description	9.	CARCAO, M. "Prophylaxis in haemophilia with inhibitors : update from international experience." Haemophilia 16.2 (2010): 16-23.
description	10.	Tatsukawa, K. "Role of Transglutaminase 2 in Liver Injury via Cross-linking and Silencing of Transcription Factor Sp1." Gastroenterology 136.5 (2009): 1783-1795.
description	11.	Hamblett, Kevin J. "Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate." Clinical cancer research 10.20 (2004): 7063-7070.
description	12.	Hoots, W Keith K. "Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial." Thrombosis and haemostasis 98.4 (2007): 726-32.
description	13.	Bhattacharyya, R. "Disulfide bonds, their stereospecific environment and conservation in protein structures." Protein engineering, design & selection 17.11 (2004): 795-808.
description	14.	CARCAO, M. "Devising a best practice approach to prophylaxis in boys with severe haemophilia : evaluation of current treatment strategies." Haemophilia 16.SUPPL. 2 (2010): 4-9.
description	15.	BLATTLER, W. "IMMUNOCONJUGATES CONTAINING NOVEL MAYTANSINOIDS - PROMISING ANTICANCER DRUGS." Cancer research 52.1 (1992): 127-131.
description	16.	Junutula, J. "Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index." Nature biotechnology 26.8 (2008): 925-932.
description	17.	"RN927C, a potent site-specific Trop-2 antibody-drug-conjugate (ADC) for treatment of solid tumors." Cancer research. 74.19.
description	18.	Xia, J. "Site-selective covalent reactions on proteinogenic amino acids." Current opinion in biotechnology 48 (2017): 220-227.
description	19.	"High frequency of Q318X mutation in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency in northeast Brazil." Arquivos brasileiros de endocrinologia e metabologia. 53.1: 40-46.
description	20.	Lundberg, J. "Does Academic Research affect Local Growth? Empirical Evidence Based on Swedish Data." Regional Studies 51.4 (2015): 1-16.